| Literature DB >> 29321674 |
Zhan Gu1, Dong Li2, Huayu He1, Jianying Wang1, Xiaojuan Hu1, Peihua Zhang2, Yanlong Hong1, Baocheng Liu3, Lei Zhang4, Guang Ji5,6.
Abstract
The purpose of this study was to compare the predictive ability of five obesity indices, including body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR), waist-to-hip ratio (WHpR) and body adiposity index (BAI), to predict multiple non-adipose metabolic risk factors, including elevated blood pressure (BP), elevated fasting plasma glucose (FPG), elevated triglyceride (TG), reduced high-density lipoprotein cholesterol (HDL-C), elevated serum uric acid (SUA) and non-alcoholic fatty liver disease (NAFLD), in an elderly Chinese population. A total of 5685 elderly Chinese subjects (≥60 years) were recruited into our community-based cross-sectional study. Receiver operating characteristic curve (ROC) analyses were used to compare the predictive ability as well as determine the optimal cut-off values of the obesity indices for multiple metabolic risk factors. According to the areas under the receiver operating characteristic curve (AUC), BMI, WC and WHtR were able to similarly predict high metabolic risk in males (0.698 vs. 0.691 vs. 0.688), while in females, BMI and WC were able to similarly predict high metabolic risk (0.676 vs. 0.669). The optimal cut-off values of BMI, WC and WHtR in males were, respectively, 24.12 kg/m2, 83.5 cm and 0.51, while in females, the values were 23.53 kg/m2 and 77.5 cm.Entities:
Mesh:
Year: 2018 PMID: 29321674 PMCID: PMC5762873 DOI: 10.1038/s41598-017-18854-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of study subjects. Data are expressed as mean± standard deviation, median (interquartile range 25–75%), or counts (percentages). WC: waist circumference; BMI: body mass index; WHtR: waist-to-height ratio; WHpR: waist-to-hip ratio; BAI: body adiposity index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; SUA: serum uric acid; BP: blood pressure; NAFLD: non-alcoholic fatty liver disease.
| Variable | Total (n = 5685) | Male (n = 2543) | Female (n = 3142) |
|
|---|---|---|---|---|
| Age (years) | 70.16 ± 7.50 | 70.05 ± 7.27 | 70.24 ± 7.67 | 0.333 |
| Height (cm) | 161.23 ± 7.62 | 167.36 ± 5.55 | 156.26 ± 5.02 | <0.001 |
| Weight (kg) | 63.14 ± 10.96 | 68.14 ± 10.33 | 59.10 ± 9.73 | <0.001 |
| WC (cm) | 81.70 ± 9.19 | 83.41 ± 8.99 | 80.32 ± 9.12 | <0.001 |
| BMI (kg/m2) | 24.22 ± 3.43 | 24.29 ± 3.23 | 24.16 ± 3.59 | 0.175 |
| WHtR | 0.51 ± 0.06 | 0.50 ± 0.05 | 0.51 ± 0.06 | <0.001 |
| WHpR | 0.88 ± 0.06 | 0.89 ± 0.06 | 0.86 ± 0.06 | <0.001 |
| BAI | 27.63 ± 4.07 | 25.26 ± 3.06 | 29.54 ± 3.77 | <0.001 |
| SBP (mmHg) | 138.45 ± 22.40 | 138.62 ± 22.06 | 138.32 ± 22.67 | 0.621 |
| DBP (mmHg) | 82.19 ± 12.39 | 81.66 ± 12.66 | 82.63 ± 12.16 | 0.003 |
| FPG (mmol/L) | 5.6(5.2–6.3) | 5.6(5.2–6.4) | 5.6(5.2–6.2) | 0.011 |
| TG (mmol/L) | 1.28(0.94–1.83) | 1.21(0.86–1.72) | 1.36(1.01–1.91) | <0.001 |
| HDL–C (mmol/L) | 1.25(1.07–1.44) | 1.16(1.02–1.35) | 1.31(1.13–1.50) | <0.001 |
| SUA (μmol/L) | 320.2(271.1–378.3) | 356.0(304.5–410.3) | 294.7(252.4–343.7) | <0.001 |
| Elevated BP | 3902 (68.64%) | 1728 (67.95%) | 2174 (69.19%) | 0.316 |
| Elevated FPG | 2997 (52.72%) | 1376 (54.11%) | 1621 (51.59%) | 0.059 |
| Elevated TG | 1688 (29.69%) | 660 (25.95%) | 1028 (32.72%) | <0.001 |
| Reduced HDL-C | 2218 (39.01%) | 711 (27.96%) | 1507 (47.96%) | <0.001 |
| Elevated SUA | 764 (13.44%) | 559 (21.98%) | 205 (6.52%) | <0.001 |
| NAFLD | 2409 (42.37%) | 1036 (40.74%) | 1373 (43.70%) | 0.025 |
Number of metabolic risk factors and obesity indices.
| N (Risk factors) N (Male/Female) | 0 (199/199) | 1 (515/573) | 2 (714/832) | 3 (558/779) | 4 (363/482) | 5 (163/256) | 6 (31/21) | ≥3 (1115/1538) |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Male | 21.90 ± 2.78 | 22.88 ± 2.94 | 24.16 ± 3.20 | 25.00 ± 2.99 | 25.85 ± 2.88 | 25.83 ± 2.62 | 26.86 ± 2.81 | 25.45 ± 2.93 |
| Female | 21.74 ± 3.04 | 22.68 ± 3.38 | 23.79 ± 3.49 | 24.68 ± 3.35 | 25.44 ± 3.21 | 26.45 ± 3.53 | 26.11 ± 3.07 | 25.23 ± 3.39 |
|
| ||||||||
| Male | 76.90 ± 7.47 | 79.46 ± 8.08 | 82.93 ± 8.39 | 85.46 ± 8.82 | 87.88 ± 8.36 | 87.38 ± 7.45 | 91.35 ± 8.11 | 86.70 ± 8.57 |
| Female | 73.85 ± 7.71 | 76.58 ± 8.81 | 79.58 ± 8.68 | 81.80 ± 8.76 | 82.97 ± 7.92 | 86.14 ± 9.01 | 86.24 ± 5.95 | 82.95 ± 8.65 |
|
| ||||||||
| Male | 0.46 ± 0.05 | 0.48 ± 0.05 | 0.50 ± 0.05 | 0.51 ± 0.05 | 0.52 ± 0.05 | 0.52 ± 0.05 | 0.55 ± 0.05 | 0.52 ± 0.05 |
| Female | 0.47 ± 0.05 | 0.49 ± 0.06 | 0.51 ± 0.06 | 0.52 ± 0.06 | 0.53 ± 0.05 | 0.55 ± 0.06 | 0.55 ± 0.04 | 0.53 ± 0.06 |
|
| ||||||||
| Male | 0.86 ± 0.06 | 0.87 ± 0.05 | 0.89 ± 0.06 | 0.90 ± 0.06 | 0.92 ± 0.05 | 0.91 ± 0.05 | 0.94 ± 0.06 | 0.91 ± 0.06 |
| Female | 0.83 ± 0.06 | 0.84 ± 0.06 | 0.86 ± 0.06 | 0.87 ± 0.06 | 0.88 ± 0.05 | 0.90 ± 0.06 | 0.90 ± 0.04 | 0.88 ± 0.06 |
|
| ||||||||
| Male | 23.54 ± 2.97 | 24.48 ± 2.90 | 25.14 ± 2.85 | 25.69 ± 3.01 | 26.30 ± 3.04 | 26.24 ± 3.10 | 26.96 ± 3.41 | 26.00 ± 3.06 |
| Female | 27.65 ± 3.42 | 28.65 ± 3.63 | 29.24 ± 3.82 | 30.00 ± 3.70 | 30.39 ± 3.37 | 30.89 ± 3.97 | 30.72 ± 3.44 | 30.28 ± 3.66 |
Area under curves (95% CI) of obesity indices for metabolic risk factors. *P value < 0.05.
| BMI | WC | WHtR | WHpR | BAI | |
|---|---|---|---|---|---|
|
| |||||
| Elevated BP | 0.626 (0.603–0.649)* | 0.613 (0.590–0.636)* | 0.623 (0.600–0.646)* | 0.593 (0.569–0.616)* | 0.606 (0.583–0.629)* |
| Elevated FPG | 0.612 (0.590–0.634)* | 0.600 (0.578–0.622)* | 0.598 (0.576–0.620)* | 0.597 (0.575–0.619)* | 0.562 (0.540–0.585)* |
| Elevated TG | 0.647 (0.624–0.670)* | 0.648 (0.625–0.671)* | 0.642 (0.619–0.666)* | 0.630 (0.606–0.654)* | 0.592 (0.567–0.616)* |
| Reduced HDL–C | 0.637 (0.614–0.660)* | 0.649 (0.627–0.672)* | 0.645 (0.622–0.668)* | 0.626 (0.603–0.650)* | 0.593 (0.569–0.617)* |
| Elevated SUA | 0.581 (0.555–0.608)* | 0.578 (0.553–0.604)* | 0.577 (0.551–0.603)* | 0.572 (0.546–0.597)* | 0.553 (0.526–0.579)* |
| NAFLD | 0.638 (0.616–0.659)* | 0.631 (0.610–0.653)* | 0.624 (0.603-0.646)* | 0.605 (0.583–0.628)* | 0.586 (0.563–0.608)* |
|
| |||||
| Elevated BP | 0.578 (0.557–0.600)* | 0.569 (0.547–0.590)* | 0.570 (0.548––0.592)* | 0.557 (0.535-0.578)* | 0.554 (0.532–0.576)* |
| Elevated FPG | 0.598 (0.578–0.618)* | 0.591 (0.572–0.611)* | 0.584 (0.564–0.603)* | 0.566 (0.546–0.586)* | 0.561 (0.541–0.581)* |
| Elevated TG | 0.615 (0.595–0.635)* | 0.601 (0.581–0.621)* | 0.590 (0.570–0.611)* | 0.576 (0.555–0.597)* | 0.563 (0.542–0.584)* |
| Reduced HDL–C | 0.621 (0.601–0.640)* | 0.632 (0.612–0.651)* | 0.622 (0.603–0.642)* | 0.615 (0.595–0.634)* | 0.576 (0.556–0.596)* |
| Elevated SUA | 0.615 (0.575–0.654)* | 0.641 (0.602–0.679)* | 0.651 (0.614–0.688)* | 0.630 (0.590–0.669)* | 0.628 (0.590–0.666)* |
| NAFLD | 0.656 (0.637–0.675)* | 0.653 (0.634–0.672)* | 0.641 (0.621–0.660)* | 0.618 (0.598–0.638)* | 0.596 (0.576–0.616)* |
.
Figure 1ROC curves of obesity indices to predict high metabolic risk population. Male (left) and female (right).
AUC, optimal cut-off values, sensitivity, specificity and Youden index of obesity indices to predict the high metabolic risk population. *P value < 0.05. **The obesity indices were able to similarly predict ≥3 metabolic risk factors using MedCalc statistical software with the algorithm developed by DeLong’s research team.
| AUC (95%CI) | Cut-off value | Sensitivity (%) | Specificity (%) | Youden index (%) | |
|---|---|---|---|---|---|
|
| |||||
| BMI | 0.698 (0.677–0.718)** | 24.12 | 67.9 | 62.5 | 30.4 |
| WC | 0.691 (0.671–0.712)** | 83.5 | 63.9 | 64.6 | 28.5 |
| WHtR | 0.688 (0.668–0.709)** | 0.51 | 56.2 | 71.6 | 27.9 |
| WHpR | 0.666 (0.646–0.687)* | 0.88 | 72.8 | 51.7 | 24.5 |
| BAI | 0.629 (0.608–0.651)* | 24.47 | 69.4 | 50.6 | 20.0 |
|
| |||||
| BMI | 0.676 (0.657–0.694)** | 23.53 | 70.0 | 57.1 | 27.1 |
| WC | 0.669 (0.650–0.688)** | 77.5 | 76.3 | 50.2 | 26.5 |
| WHtR | 0.659 (0.640–0.678)* | 0.49 | 76.4 | 47.4 | 23.8 |
| WHpR | 0.632 (0.613–0.652)* | 0.85 | 71.0 | 49.6 | 20.6 |
| BAI | 0.614 (0.595–0.634)* | 27.82 | 74.9 | 42.3 | 17.2 |